期刊文献+

慢性乙型肝炎抗病毒治疗进展 被引量:4

下载PDF
导出
摘要 慢性乙型肝炎( chronic hepatitis B ,CHB)是严重健康问题之一。全球CHB约3.5亿,是导致肝硬变和肝细胞癌( hepatocellular carcinoma, HCC )的主要原因之一[1],部分伴肝脂肪变性[2]对CHB 预后有一定影响。我国是CHB高发区, HBsAg 携带者1.2亿,慢性病例约1200万,每年约30万人死于肝病。 CHB的治疗目标是最大限度地抑制乙型肝炎病毒( hepatitis B virus,HBV),减轻肝脏炎症坏死及纤维化,延缓疾病进展,减少肝脏失代偿、肝硬变、HCC 及其并发症的发生,改善患者生活质量和延长存活时间。治疗原则包括抗病毒、免疫调节、抗炎、抗纤维化等。目前认为抗病毒是CHB治疗的关键。抗病毒药物主要作用是提高机体免疫清除能力和抑制病毒复制。美国、欧洲国家、亚太地区国家以及我国先后制定和修订的CHB治疗指南[3]或共识,为有效抑制病毒起了重要作用。
作者 刘自贵
出处 《现代临床医学》 2014年第3期233-237,共5页 Journal of Modern Clinical Medicine
  • 相关文献

参考文献9

  • 1Denis Ouzan,Guillaume Pénaranda,Hélène Joly,Hacène Khiri,Antonnella Pironti,Philippe Halfon.Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J].Journal of Clinical Virology.2013(4)
  • 2Q. Li,G. Dong,J. Yu,C. Sun,S. Xie.757 ADDING PEGINTERFERON alfa-2a ON NUCLEOS(T)IDE ANALOGUES THERAPY IMPROVES HBeAg SEROCONVERSION AND qHBsAg DECLINE IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS WHO HAVE ACHIEVED VIROLOGICAL RESPONSES[J].Journal of Hepatology.2013
  • 3X.F. Chen,X.P. Chen,X.J. Ma,W.L. Chen.741 OPTIMIZED STRATEGY: SEQUENTIAL PEGYLATED INTERFERON a-2a THERAPY IN ENTECAVIR-TREATED PATIENTS CHB WITHOUT SATISFACTORY END-POINT LED TO HBeAg SEROCONVERSION[J].Journal of Hepatology.2013
  • 4Jens M. Kittner,Martin F. Sprinzl,Annette Grambihler,Arndt Weinmann,J?rn M. Schattenberg,Peter R. Galle,Marcus Schuchmann.Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J].Journal of Clinical Virology.2012(1)
  • 5Shi-Wu Ma,Xuan Huang,Yong-Yin Li,Li-Bo Tang,Xiao-Feng Sun,Xiao-Tao Jiang,Yue-Xin Zhang,Jian Sun,Zhi-Hua Liu,William G.H. Abbott,Yu-Hong Dong,Nikolai V. Naoumov,Jin-Lin Hou.High serum IL-21 levels after 12<ce:hsp sp="0.25"/>weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B[J].Journal of Hepatology.2011(4)
  • 6Hui Nie,Alison A. Evans,W. Thomas London,Timothy M. Block,Xiangdong David Ren.Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion[J].Journal of Hepatology.2011(4)
  • 7Jorge Joven,Eugenia Espinel,Anna Rull,Raúl Beltrán-Debón,Gerard Aragonès,Esther Rodríguez-Gallego,Jordi Camps,Juan Pedro-Botet,Teresa Sans,Javier A. Menéndez,Carlos Alonso-Villaverde.Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis[J].Journal of Clinical Virology.2011(3)
  • 8Anna Suk‐FongLok.Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?[J].Journal of Gastroenterology and Hepatology.2011(2)
  • 9Emanuel K. Manesis,George V. Papatheodoridis,Dina G. Tiniakos,Emilia S. Hadziyannis,Olga P. Agelopoulou,Thalia Syminelaki,Christos Papaioannou,Theodoros Nastos,Peter Karayiannis.Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B[J].Journal of Hepatology.2010(1)

共引文献4

同被引文献49

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部